Trieu Vuong 4
4 · Oncotelic Therapeutics, Inc. · Filed Nov 19, 2025
Insider Transaction Report
Form 4
Trieu Vuong
DirectorCHAIRMAN AND CEO10% Owner
Transactions
- Award
Series A Convertible Preferred Stock
2025-11-17+4,065→ 4,065 total→ Com-mon Stock (4,065,000 underlying)
Footnotes (2)
- [F1]Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis.
- [F2]The shares of Series A Convertible Preferred Stock were issued to Dr. Trieu as compensation pursuant to the accomplishment of performance milestones under a Restricted Stock Agreement dated November 17, 2025.